Oxytocin
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Oxytocin is listed as reproductive / neuropeptide.
- •Labor Induction
- •Postpartum Hemorrhage
Regulatory status: FDA-Approved Rx.
Structure & Properties
Compound: Oxytocin; also known as Pitocin, Syntocinon.
Pharmacologic class: Reproductive / Neuropeptide.
Known delivery routes: Intravenous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Oxytocin receptor agonist — uterine contraction and hemostasis; CNS roles in bonding and social behavior.
- •Effective labor induction/augmentation
- •PPH prevention and treatment
Human Research
Evidence grade: Clinical RCT (Phase III)
Clinical RCT (Phase III). Extensive obstetric trial data.
Laboratory Research
Extensive obstetric trial data
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Clinician-administered IV/IM in labor/postpartum settings.
Potential interactions and combinations to avoid
- •Prostaglandin cervical ripening agents in the same window
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Uterine hyperstimulation
- •Fetal distress
- •Water intoxication
- •Hyponatremia
Contraindications
- •Cephalopelvic disproportion
- •Fetal distress
- •Placenta previa
- •Prior classical uterine incision
- •Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- •Undiagnosed abnormal uterine or vaginal bleeding
- •Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- •Precocious puberty or unresolved pituitary pathology
- •History of thromboembolism or ovarian hyperstimulation syndrome
- •Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- •Bipolar disorder, psychosis, or active mania
- •Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- •Recent intracranial haemorrhage or unstable neurologic injury
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Cephalopelvic disproportion, fetal distress, or unfavourable fetal position
- •Prolonged use with hypotonic uterine inertia
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 0.5–20 mU/min (IV titration)
Frequency: Continuous IV
Cycling: Continuous IV titration; not for outpatient cycling.
IV Infusion
Labor induction / augmentation, postpartum hemorrhage.
IV pump, dilute per protocol. Titrated infusion under continuous fetal monitoring.
Intramuscular
Postpartum hemorrhage prophylaxis.
1 mL syringe, 21G. 10 IU IM after delivery of anterior shoulder or placenta.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Standard obstetric protocols
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
As needed — intranasal 15–30 min before social/intimate situations.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- IV — clinician only — Antecubital vein or central line. Not for home administration.
- Ventrogluteal — Palm on greater trochanter, index to ASIS — inject in the V. Safest IM site.
- Anterior thigh (vastus lateralis) — Middle third of the outer front thigh. Preferred IM site for self-injection.
- Upper arm / deltoid — Back of the upper arm for SubQ; 2 in below the shoulder bone for IM.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous IV titration; not for outpatient cycling.
Timing & Interactions
- ·Prostaglandin cervical ripening agents in the same window
- ·Standard obstetric protocols
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Oxytocin and sync them to Vial Lab.
Benefits
- ·Effective labor induction/augmentation
- ·PPH prevention and treatment
Risks
- ·Uterine hyperstimulation
- ·Fetal distress
- ·Water intoxication
- ·Hyponatremia
Contraindications
- ·Cephalopelvic disproportion
- ·Fetal distress
- ·Placenta previa
- ·Prior classical uterine incision
- ·Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- ·Undiagnosed abnormal uterine or vaginal bleeding
- ·Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- ·Precocious puberty or unresolved pituitary pathology
- ·History of thromboembolism or ovarian hyperstimulation syndrome
- ·Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- ·Bipolar disorder, psychosis, or active mania
- ·Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- ·Recent intracranial haemorrhage or unstable neurologic injury
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Cephalopelvic disproportion, fetal distress, or unfavourable fetal position
- ·Prolonged use with hypotonic uterine inertia
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx
Veterinary Use (Pets)
No established veterinary protocol for Oxytocin. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.